Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964442 | 0.80 | — | — | |
| SCHEMBL288016 | 0.71 | — | — | |
| SCHEMBL29376210 | 0.71 | — | — | |
| SCHEMBL6399596 | 0.69 | — | — | |
| SCHEMBL160466 | 0.69 | ADRA2A (0.32) | ADRA2AADRA2BADRA2C | |
| SCHEMBL3939166 | 0.69 | ADRA2A (0.32) | ADRA2AADRA2BADRA2C | |
| SCHEMBL870281 | 0.69 | ADRA2A (0.38) | ADRA2AADRA2BADRA2C | |
| SCHEMBL2923845 | 0.69 | ADRA2A (0.32) | ADRA2AADRA2BADRA2C | |
| SCHEMBL18633926 | 0.69 | ADRA2A (0.32) | ADRA2AADRA2BADRA2C | |
| SCHEMBL38950 | 0.68 | NNMT (0.44) | ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | claimed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | claimed |
| CN-113348168-A | Heterocyclic derivatives | 默克专利有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-113195053-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2021-07-30 | — | — | CN | claimed |
| CN-112689507-A | Amino acid compounds having unbranched linkers and methods of use thereof | 普利安特治疗公司 | 2021-04-20 | — | — | CN | claimed |
| US-20200123151-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-23 | — | — | US | claimed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | claimed |
| EP-2834221-B1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | EP | claimed |
| EP-2078009-B1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI SA (FR) | 2015-03-18 | — | — | EP | claimed |
| EP-1539739-B1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-24 | — | — | EP | claimed |
| US-20100130503-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI-AVENTIS (FR) | 2010-05-27 | — | — | US | claimed |
| US-20090203745-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-08-13 | — | — | US | claimed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | claimed |
| EP-2024357-A2 | NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jereni AG (DE) | 2009-02-18 | — | — | EP | claimed |
| EP-1979342-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jerini AG (DE) | 2008-10-15 | — | — | EP | claimed |
| WO-2007131764-A2 | NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-11-22 | — | — | WO | claimed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | claimed |
| US-20020099210-A1 | Propanoic acid derivatives as integrin inhibitors | CELLTECH CHIROSCIENCE LTD. (GB) | 2002-07-25 | — | — | US | claimed |
| WO-2001044194-A2 | PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2001-06-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203745-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | ITGB1, ITGA2, ITGB2 | ADRA2A 186/4885ADRA2B 199/4885ADRA2C 189/4885 |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | ADRA2A 2087/4885ADRA2B 1725/4885ADRA2C 2533/4885 |
| US-20200123151-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | ADRA2A 780/4885ADRA2B 234/4885ADRA2C 2389/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | ADRA2A 2087/4885ADRA2B 1725/4885ADRA2C 2533/4885 |
| US-20020099210-A1 | Propanoic acid derivatives as integrin inhibitors | ITGA1, ITGB1, ITGB7 | ADRA2A 161/4885ADRA2B 98/4885ADRA2C 283/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | ADRA2A 1826/4885ADRA2B 1450/4885ADRA2C 2534/4885 |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | ITGA1, ITGB1, ITGA5 | ADRA2A 87/4885ADRA2B 71/4885ADRA2C 105/4885 |
| US-20100130503-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | HSP90AB2P, HSPA2, HSP90AB1 | ADRA2A 2705/4885ADRA2B 2868/4885ADRA2C 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.